N/A
N=19
The Cardiovascular Effects of Electronic Hookah Vaping
Endothelial Dysfunction · Inflammation · Oxidative Stress
Bottom Line
View on ClinicalTrials.gov: NCT03690427 ↗Enrolled (actual)
19
Serious AEs
0.0%
Results posted
Aug 2023
Primary outcome: Primary: Flow-Mediated Dilation (FMD) — 6.11; 5.89; 4.79; 7.31 percentage of arterial diameter
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Traditional hookah smoking (Other); Electronic hookah vaping (Other)
- Age
- Adult · 21+ yrs
- Sex
- All
- Sponsor
- University of California, Los Angeles
- Primary completion
- Aug 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Flow-Mediated Dilation (FMD) |
9.46; 8.74 | — |
| PRIMARY Carotid-Femoral Pulse Wave Velocity (Cf-PWV) |
8.20; 8.15; 8.94; 8.71 | — |
| PRIMARY HDL Oxidant Index (HOI) |
0.57; 0.56; 0.58; 0.52 | — |
| PRIMARY Paraoxonase-1 (PON-1) Activity |
1071.24; 709.32; 1151.73; 701.29 | — |
| PRIMARY Arylesterase Activity |
277.36; 281.38; 295.78; 285.06 | — |
| PRIMARY High-sensitivity C-reactive Protein (Hs-CRP) Levels |
0.72; 0.77; 0.76; 0.77 | — |
| PRIMARY Tumor Necrosis Factor-α (TNFα) Concentrations |
0.69; 0.85; 0.76; 0.82 | — |
| SECONDARY Flow-Mediated Dilation (FMD) |
9.46; 8.74 | — |
| SECONDARY Endothelium-independent Vasodilator Function (Control Test for Endothelium-dependent Vasodilator Function) |
27.15; 25.17 | — |
| SECONDARY Augmentation Index (AI) |
7.97; 7.79; 13.55; 10.66 | — |
| SECONDARY Interleukin 6 (IL-6) Levels |
0.13; 0.04 | — |
| SECONDARY Interleukin 10 (IL-10) Levels |
0.03; -0.01 | — |
| SECONDARY Nicotine Levels |
0.59; 0.82; 5.83; 6.96 | — |
| SECONDARY Carbon Monoxide (CO) Levels |
2.58; 3.38; 2.31; 40.19 | — |
Summary
Hookah (water-pipe) tobacco smoking has quickly grown to become a major global tobacco epidemic among youth; with electronic (e-) hookahs more recently increasing in popularity especially among young female adults, who endorse marketing claims that these products are a safer alternative to traditional hookah, but scientific evidence is lacking. The study aims to elucidate the comparative effects of traditional hookah smoking vs. e-hookah vaping on human vascular and endothelial function; and examine the role of inflammation and oxidative stress, as likely mechanisms in hookah-related cardiovascular disease pathogenesis.
Eligibility Criteria
Inclusion Criteria
- 21-39 years old hookah smokers: smoked hookah >12x in last 12 months
- no history of illicit drugs or marijuana
- no evidence of cardiopulmonary disease by history/ physical
- no diabetes: fasting blood glucose 10 ppm (smoking non-abstinence)
- positive pregnancy test
- psychiatric illness
Data sourced from ClinicalTrials.gov (NCT03690427). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.